Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

NDA FilingdaraxonrasibPositive

AI Analysis

Summary

Revolution Medicines' NDA for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, was accepted for FDA review for previously treated metastatic pancreatic ductal adenocarcinoma. This represents a significant regulatory milestone for the targeted therapy program.

Outcome Details

NDA accepted for review by FDA

Importance:7/10

Sentiment:

0.70

NDA acceptancepancreatic cancerRAS inhibitorFDA reviewoncology

Related Companies

$RVMD

Read the original article

Published by GlobeNewswire Clinical Studies on July 22, 2026 8:05 PM

Read Original